These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32285102)

  • 1. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.
    Murray B; Wolfe C; Marra A; Pillar C; Shinabarger D
    J Antimicrob Chemother; 2020 Aug; 75(8):2149-2155. PubMed ID: 32285102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
    Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.
    Bassères E; Begum K; Lancaster C; Gonzales-Luna AJ; Carlson TJ; Miranda J; Rashid T; Alam MJ; Eyre DW; Wilcox MH; Garey KW
    J Antimicrob Chemother; 2020 Oct; 75(10):2879-2884. PubMed ID: 32719870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.
    McPherson J; Hu C; Begum K; Wang W; Lancaster C; Gonzales-Luna AJ; Loveall C; Silverman MH; Alam MJ; Garey KW
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0224421. PubMed ID: 35862742
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Oka D; Yamaya N; Kuno T; Asakawa Y; Shiragiku T; Chen L; Xue J; Mamuti A; Ye F; Sun J; Ohguro K; Miyamoto H; Uematsu Y; Inagaki K; Cheng JF; Matsumoto M
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
    Corbett D; Wise A; Birchall S; Warn P; Baines SD; Crowther G; Freeman J; Chilton CH; Vernon J; Wilcox MH; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1751-6. PubMed ID: 25652750
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Begum K; Bassères E; Miranda J; Lancaster C; Gonzales-Luna AJ; Carlson TJ; Rashid T; Eyre DW; Wilcox MH; Alam MJ; Garey KW
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
    Takeda S; Miki T
    Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019-2021.
    Tsai CS; Lu PL; Lu MC; Hsieh TC; Chen WT; Wang JT; Ko WC
    J Microbiol Immunol Infect; 2024 Apr; 57(2):320-327. PubMed ID: 38135646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.
    Karlowsky JA; Adam HJ; Baxter MR; Dutka CW; Nichol KA; Laing NM; Golding GR; Zhanel GG
    J Antimicrob Chemother; 2020 Jul; 75(7):1824-1832. PubMed ID: 32294172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The
    Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
    Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.
    Garey KW; Begum K; Lancaster C; Gonzales-Luna A; Bui D; Mercier J; Seng Yue C; Ducharme MP; Hu M; Vince B; Silverman MH; Alam MJ; Kankam M
    J Antimicrob Chemother; 2020 Dec; 75(12):3635-3643. PubMed ID: 32892222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting against Clostridioides difficile infection: Current medications.
    Quan M; Zhang X; Fang Q; Lv X; Wang X; Zong Z
    Int J Antimicrob Agents; 2024 Jul; 64(1):107198. PubMed ID: 38734214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
    Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.